Bausch Health Companies Inc. (BHC)
Chart Events
Performance Outlook
| Previous Close | 28.15 |
| Open | 28.58 |
| Bid | 28.91 x 1100 |
| Ask | 29.54 x 800 |
| Day's Range | 28.22 - 29.13 |
| 52 Week Range | 14.86 - 34.80 |
| Volume | 1,738,500 |
| Avg. Volume | 4,405,671 |
| Market Cap | 10.369B |
| Beta (5Y Monthly) | 1.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.86 |
| Earnings Date | Aug 04, 2021 - Aug 09, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Nov 10, 2010 |
| 1y Target Est | 35.33 |
Fair Value
Related Research
- PR Newswire
New National Eye Institute Data Shows AREDS2 Nutrient Formula Continues To Reduce The Risk Of Moderate To Advanced Age-Related Macular Degeneration Progression
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced new data from the National Eye Institute (NEI) 10-Year Follow-on Study Results of the Age-Related Eye Disease Study 2 (AREDS2), which reaffirms the clinical outcomes of the AREDS2 study. Based on this data, the NEI continues to recommend a specific nutrient formula to help reduce the risk of progression in patients with moderate to advanced Age-Related Macular Degeneration (AMD).1 That formula is currently found in Bausch + Lomb PreserVision® AREDS 2 Formula eye vitamins, which was provided to participants in the last five years of the follow-on study. The study results were presented at the Association for Research in Vision and Ophthalmology annual meeting on May 7, 2021."These new, longer-term results from the NEI build on the findings of previous AREDS studies, which show that a precise mix and dosage of specific vitamins, minerals and antioxidants can help reduce the risk of progression in people who have moderate to advanced AMD," said Rishi P. Singh, M.D., professor of ophthalmology, Lerner College of Medicine, and staff surgeon at the Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio. "These findings further clarify the importance of an AREDS2 supplement as part of a patient's plan, and the need for eye care professionals to provide a specific recommendation for this formulation in appropriate patients." The NEI's 10-Year Follow-on Study of AREDS2 analysis included 3,887 people (6,360 study eyes) with intermediate to advanced AMD over a 10 year period. The study further validated the original findings about the AREDS2 formulation with 80mg of zinc and provided support for the continued benefit of lutein and zeaxanthin, which were shown to have an incremental beneficial effect as compared to beta-carotene.1
- Insider Monkey
Were Hedge Funds Right About Piling Into Bausch Health Companies Inc. (BHC)?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 887 world-class investment firms that we track and now have access to the collective wisdom contained in […]
- PR Newswire
Bausch Health Announces Participation In Upcoming Investor Conferences
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that the Company will participate in multiple upcoming investor conferences.
